Only information I’ve heard this week that has some...

Only information I’ve heard this week that has some connection…

“Sanofi is set to acquire Vigil Neuroscience, which as the name implies is a biotech company focused on neurodegenerative diseases in a $470 million deal.Under the terms of the agreement, Sanofi will acquire all outstanding common shares of Vigil for $8 per share in cash. In addition, Vigil shareholders will receive a non-transferrable CVR for each Vigil share, which will entitle its holders to receive a deferred cash payment of $2 per share, conditioned upon the first commercial sale of its drug, VG3927.VG3927 is a phase 1 small molecule drug meant to treat Alzheimer's. Similar drugs have been developed and approved by the FDA and are made by Eli Lilly and Likwembe, which is a joint venture between Biogen and the Japanese pharmaceutical company, Isai”
From The Special Situations Report: A Biotech Boom: Rumored Deals, Bidding Wars, CVRs, Insider Transactions, and More! – The Special Situations Report Episode #22, 9 Jun 2025https://podcasts.apple.com/ca/podcast/the-special-situations-report/id1790149530?i=1000712073290&r=659This material may be protected by copyright.